1-3 of 3
Eva Hoster, MSc
Close
Sort by
Journal Articles

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Wolfgang Hiddemann, MD, PhD, Eva Hoster, MSc, Christian Buske, MD, PhD, Martin Dreyling, MD, PhD, Michael Kneba, MD, PhD, Michael Hallek, MD, PhD, Eva Lengfelder, MD, Hannes Wandt, MD, PhD, Michael Unterhalt, MD
Journal: Blood
Blood (2006) 108 (11): 483.
https://doi.org/10.1182/blood.V108.11.483.483
Published: 2006
Journal Articles

Improvement of Overall Survival in Mantle Cell Lymphoma during the Last Decades.

Annina Herrmann, MSc, Eva Hoster, MSc, Martin Dreyling, MD, PhD, Michael Unterhalt, MD, Günter Brittinger, MD, PhD, Wolfgang Hiddemann, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2446.
https://doi.org/10.1182/blood.V108.11.2446.2446
Published: 2006
Journal Articles

The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP).

Christian Buske, MD, Eva Hoster, MSc, Martin Dreyling, MD, Joerg Hasford, MD, Michael Unterhalt, MD, PhD, Wolfgang Hiddemann, MD, PhD, On behalf of the German Low Grade Lymphoma Study Group (GLSG)
Journal: Blood
Blood (2005) 106 (11): 925.
https://doi.org/10.1182/blood.V106.11.925.925
Published: 2005